ArticleDiscover oncology2025
Mendelian randomization reveals immune cell composition as a key determinant of cervical cancer prognosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is still a major public health problem, and understanding the complex interplays in the tumor microenvironment is essential to implementing better clinical outcome measures. In this study, we used a Mendelian Randomization-based strategy to assess the causal roles of immune cell composition and disease prognosis in cervical cancer.
methodsThe authors employed genetic natural experiments to measure the relationship between monocyte absolute counts, CD4-CD8-T cell ratios, and CD24 levels on memory B cells and indicators of cervical cancer prognosis.
resultsMendelian Randomization analysis showed that higher monocyte absolute counts were associated with a better prognosis, implying a protective role of these cells. In contrast, compared to individuals with good prognosis, high CD4-CD8-T cell ratios and low CD24 expression on memory B cells associated with bad prognosis suggest a risk-promoting role of these immune cell subsets. These observations were also further supported by additional analyses, such as scatter plots and linear regression models, which revealed further nuances in the intricate relationship between the immune microenvironment and the disease.
conclusionOur study utilizing the Mendelian Randomization approach provides novel insights into the causal relationships between the immune microenvironment of cervical cancer and its prognosis. The identified immune cell markers (monocyte counts, T cell ratios) have the potential to serve as prognostic biomarkers and to inform the design of targeted immunotherapeutic approaches in cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.